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On Oct 5, 2015, we launch the ﬁ rst 45 disease-speciﬁ c 
pages of a major new online initiative involving all Lancet 
journals that will bring together an overview Seminar 
and relevant Reviews, Clinical Series, Commissions, 
research, Case Reports, and Clinical Pictures. Over the 
next 18 months or so when The Lancet Clinic is complete, 
there will be online pages for 135 diseases, which we 
have identiﬁ ed by a combination of global burden of 
disease data and clinical practice needs. We hope that 
The Lancet Clinic will help practising doctors make better 
informed decisions that ultimately lead to better lives of 
people worldwide, and help others who want to educate 
or update themselves keep abreast of the evolving 
evidence base. Importantly, these pages will be updated 
at regular intervals. The authors of newly commissioned 
Seminars have agreed to provide regular summaries of 
important new evidence for 4 years. Individual clinical 
editors will pull together newly published material from 
across the Lancet journals and post links to these on the 
page regularly.
In addition, we are continuing our regular editorial 
policies of commissioning more specialised Clinical 
Reviews and Series across The Lancet Group to 
provide a more focused and in-depth assessment 
for key diseases. And beyond providing knowledge 
and information, we want to encourage academic 
and practising clinicians to use this knowledge for 
advocacy and change. In 2014, The Lancet published 
the ﬁ rst Clinical Commission on liver disease in the 
UK and in February, 2015, we launched our ﬁ rst 
Clinical Campaign based on this Commission. A 
Cancer Campaign as a joint eﬀ ort between The Lancet 
and The Lancet Oncology followed in April. Clinical 
Campaigns aim to eﬀ ect change based on data, 
In an age of instant communications and instant 
opinions, when every item of news or celebrity in-
discretion is liable to be pored over on social media, it 
seems unfortunate that readers of The Lancet Infectious 
Diseases have to wait for months to have their views 
on articles published via the correspondence columns. 
Recognising this need, we are improving the speed 
and ease with which readers can express opinions on 
papers by launching a readers’ comments facility. On the 
journal’s website (http://www.thelancet.com/journals/
laninf), every item published has a comment box on 
the right side of the screen. Commenting is open to all 
registered users of the website. Submitted comments 
will be moderated by the journal’s editors to ensure that 
they are relevant, appropriate, and comprehensible. 
Authors must put their name and those of any co-
authors at the bottom of the text of the comment, and 
give an aﬃ  liation for every author. We will aim to post 
approved comments within 1 business day. Please read 
the guidelines before posting a comment.  
We are—we admit—rather late to this party, with the 
BMJ, for example, having had such a service since the 
late 1990s. Indeed, some news sites have closed their 
comments sections recently because they have become 
too hard to manage.1,2 Social media has perhaps taken 
over some of the role of comments sections. However, 
the 140 character limit of Twitter does not permit much 
nuance in the scientiﬁ c debate, and we believe that our 
online comments section will allow a more immediate 
connection with the journal’s readership. 
The comment facility will be open initially for 
6 months. If after this period the quality of comments 
received is poor, the section is little used, or, conversely, 
its management is beyond our resources, we will 
reconsider its future. If successful, we would ultimately 
like to replace correspondence letters with comments 
received online. However, that is a decision for the 
future, and for now the journal will continue to publish 
correspondence in monthly issues.
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knowledge, and expert interpretation in partnership 
with others. Further Clinical Commissions on asthma, 
hypertension, dementia, tuberculosis, traumatic 
brain injury, psychotherapy, chronic obstructive 
pulmonary disease, and others are underway across all 
Lancet journals. With these Clinical Commissions and 
Campaigns, we hope to extend our goal to publish the 
best science for better lives to being an active partner 
in using this science for actual change. Commissions 
and Campaigns will be part of the disease pages to 
encourage engagement and actions. The Lancet Clinic 
invites you to be part of this endeavour.
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